Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sage Ready To Turn Over Cards On Bets Outside Of Depression

Five Clinical Trial Readouts Expected In 2024

Executive Summary

Sage has two postpartum depression drugs on the market, but will read out mid-stage trials this year for two candidates in Huntington’s, Parkinson’s and Alzheimer’s diseases and essential tremor.

You may also be interested in...

Sage Sees New Diagnosis Trend In PPD As Zurzuvae Launch Gets Off The Ground

It’s early days in the launch of Zurzuvae for postpartum depression, but Sage highlighted encouraging prescription trends during the company’s fourth quarter sales and earnings call.

J.P. Morgan Day Four: Roche Sees Lots Of Partnering Interest, While Bluebird, Sage Offer Launch Updates

Daily notebook from the J.P. Morgan Healthcare Conference:  Roche expects continued high interest in partnering; Vir explains cost-cutting gives it a stronger base; bluebird provides Lyfgenia performance to date; Sage details Zurzuvae launch trajectory; and Madrigal lays out next steps in NASH. 

Sage Readies Zurzuvae For December Launch With Slow Ramp As Payer Talks Progress

Sage and Biogen set a $15,900 list price for Zurzuvae, the 14-day postpartum depression drug approved in the US in August, and expect broad access but formulary discussions will continue into 2024.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts